You are here: Industry Insights > Samsung Biologics

News List

Samsung Biologics Expands Global Footprint contractpharma
November 02, 2020
Samsung Biologics has opened its first U.S. CDO R&D Center in San Francisco, CA, bringing its contract development services closer to global clients.
Samsung Biologics expands global footprint with opening of new San Francisco CDO R&D Center prnasia
October 29, 2020
At a virtual ceremony today, Samsung Biologics announced the grand opening of its first US CDO R&D Center in San Francisco, bringing its contract development services closer to global clients.
Samsung Biologics, Dinona Partner on Potential COVID-19 Antibody Therapy contractpharma
October 22, 2020
Will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.
Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing prnasia
October 21, 2020
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases prnasia
September 27, 2020
Samsung Biologics and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply prnasia
September 22, 2020
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as...
PharmAbcine Partners with Samsung Biologics for PMC-403 contractpharma
September 22, 2020
The antibody is expected to enter a global ophthalmological clinical trial in 2022.
Samsung Biologics Inks Service Pact with Panolos Bioscience contractpharma
September 18, 2020
Will provide cell line development, process development, and clinical material manufacturing for PB101, an Fc-fusion protein to treat solid tumors.
Samsung Biologics signs development agreement with Panolos for solid tumor treatment prnasia
September 17, 2020
Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.
Samsung Biologics Expands Footprint contractpharma
August 13, 2020
Will break ground on its fourth plant this year, adding 256KL of capacity.

Previous page 1 2 3 4 5 6 Next page